Premium
Management of COPD in Asia: A position statement of the Asian Pacific Society of Respirology
Author(s) -
Rhee Chin Kook,
Chau Ngo Quy,
Yunus Faisal,
Matsunaga Kazuto,
Perng DiahnWarng
Publication year - 2019
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.13633
Subject(s) - medicine , copd , bronchiectasis , pulmonary disease , asia pacific , disease , pulmonary function testing , intensive care medicine , environmental health , lung , international trade , business
Chronic obstructive pulmonary disease (COPD) is a major disease in Asia. However, how to manage specifically Asian COPD patients has not been proposed. Awareness of COPD is very low and underdiagnosis/undertreatment is common in Asian countries. Low utilization of pulmonary function test and inhalers is also a problem. Moreover, high smoking prevalence and air pollution are barriers to managing Asian patients with COPD. The relatively low body mass index of Asian patients with COPD can increase their risk for experiencing adverse effects from COPD drugs. Physicians should consider the unique features of Asian populations with COPD such as the high prevalence rates of bronchiectasis and tuberculosis‐destroyed lungs, biomass smoke exposure and parasitic infection.